Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura J Esserman

Showing results (241-250 of 308) with videos related to

Pageof 31
Sort By:
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 24, 2018
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trialDavid C Newitt, Zheng Zhang, Jessica E Gibbs, et al.
JAMA Oncology|May 31, 2026
Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM StudyYiwey Shieh, Rachel S Heise, Lisa Madlensky, et al.
Journal of the National Cancer Institute|January 24, 2018
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast CancerLinda S Lindström, Christina Yau, Kamila Czene, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 3, 2006
Genetic/familial high-risk assessment: breast and ovarianMary B Daly, Jennifer E Axilbund, Eileen Bryant, et al.
The Lancet. Respiratory Medicine|May 15, 2026
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, studyD Clark Files, Michael A Matthay, Andrew G Chapple, et al.
Science Translational Medicine|April 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancerXiaopeng Sun, Andres A Ocampo, Ann Hanna, et al.
Nature Communications|June 27, 2022
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancerJoyce V Lee, Filomena Housley, Christina Yau, et al.
Nature Communications|November 22, 2022
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancerJoyce V Lee, Filomena Housley, Christina Yau, et al.
Pageof 31

Showing results (241-250 of 308) with videos related to

Sort By:
Pageof 31
NPJ Breast Cancer|January 5, 2021
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefitSanne Løkkegaard, Daniel Elias, Carla L Alves, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 11, 2011
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031Matthew J Ellis, Vera J Suman, Jeremy Hoog, et al.
Journal of Magnetic Resonance Imaging : JMRI|October 24, 2018
Test-retest repeatability and reproducibility of ADC measures by breast DWI: Results from the ACRIN 6698 trialDavid C Newitt, Zheng Zhang, Jessica E Gibbs, et al.
JAMA Oncology|May 31, 2026
Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM StudyYiwey Shieh, Rachel S Heise, Lisa Madlensky, et al.
Journal of the National Cancer Institute|January 24, 2018
Intratumor Heterogeneity of the Estrogen Receptor and the Long-term Risk of Fatal Breast CancerLinda S Lindström, Christina Yau, Kamila Czene, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 3, 2006
Genetic/familial high-risk assessment: breast and ovarianMary B Daly, Jennifer E Axilbund, Eileen Bryant, et al.
The Lancet. Respiratory Medicine|May 15, 2026
Biological subphenotypes in severe acute hypoxaemic respiratory failure and acute respiratory distress syndrome using rapid prospective classification (SPARC) in the USA: a multicentre, observational, studyD Clark Files, Michael A Matthay, Andrew G Chapple, et al.
Science Translational Medicine|April 22, 2026
Peripheral blood transcriptional profiling predicts tumor subtype and neoadjuvant chemoimmunotherapy outcomes in human breast cancerXiaopeng Sun, Andres A Ocampo, Ann Hanna, et al.
Nature Communications|June 27, 2022
Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancerJoyce V Lee, Filomena Housley, Christina Yau, et al.
Nature Communications|November 22, 2022
Author Correction: Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancerJoyce V Lee, Filomena Housley, Christina Yau, et al.
Pageof 31